Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases

BACKGROUND: Antiangiogenic therapy has proved to be an important therapeutic tool for many retinal vascular diseases; however, its availability is limited in developing countries. This study sought to describe the bevacizumab vial sharing process and to evaluate the impact of this repackaging system...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Public Health
Egile Nagusiak: Sodré, Sávio Lima, Barbosa, Italo Antunes França, Pacheco, Israel Emiliano, Ferreira, Felipe de Queiroz Tavares, David, Milton Agrizzi, Nascimento, Mauricio Abujamra, Arieta, Carlos Eduardo Leite, Vasconcellos, Jose Paulo Cabral de
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6740002/
https://ncbi.nlm.nih.gov/pubmed/31510981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12889-019-7562-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak